Credit Suisse analyst Scott Deuschle maintains Lockheed Martin (NYSE:LMT) with a Underperform and raises the price target from $375 to $384.
Rubius Therapeutics To Present Trials In Progress Poster For The Phase 1/2 Clinical Trial Of Rtx-224 In Select Advanced Solid Tumors At The 2022 American Society Of Clinical Oncology Annual Meeting
Rubius Therapeutics to Present Trials in Progress Poster for the Phase 1/2 Clinical Trial of RTX-224 in Select Advanced Solid Tumors at the 2022 American Society of Clinical Oncology Annual Meeting
CAMBRIDGE, Mass., May